ONGENTYS
Peakopicapone
NDAORALCAPSULE
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
5/8 — Partial
ONGENTYS (opicapone) is catechol o-methyltransferase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONGENTYS (opicapone) is an oral capsule catechol O-methyltransferase (COMT) inhibitor approved by the FDA on April 24, 2020. It is indicated as an adjunctive treatment for Parkinson's disease patients experiencing motor fluctuations on levodopa-based therapy. The drug works by inhibiting COMT, an enzyme that metabolizes dopamine, thereby extending the duration of levodopa's therapeutic effect and reducing off-time periods. ONGENTYS represents a complementary option in the Parkinson's disease treatment arsenal for managing end-of-dose motor complications.
$0.0BPart D
6.6 years to LOEMechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
Started Nov 2021
106 enrolled
Parkinson Disease
OpicApone Sleep dISorder
Started Jun 2021
22 enrolled
Parkinson Disease
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
Started May 2021
410 enrolled
Parkinson
Opicapone Treatment Initiation Open-Label Study
Started Mar 2021
239 enrolled
Parkinson Disease
OpiCapone Effect on Motor Fluctuations and pAiN
Started Feb 2021
144 enrolled
Parkinson Disease
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.